Neural Therapeutics (XCNQ:NURL) EPS (Basic): C$0.00 (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics EPS (Basic)?

Neural Therapeutics XCNQ:NURL EPS (Basic) is C$0.00 as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jan. 2026 was C$0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2026 was C$0.00.

Neural Therapeutics's EPS (Diluted) for the three months ended in Jan. 2026 was C$-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 was C$-0.01.

Neural Therapeutics's EPS without NRI for the three months ended in Jan. 2026 was C$-0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2026 was -0.01.

During the past 3 years, the average EPS without NRI Growth Rate was -7.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -52.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Neural Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -7.70% per year. The lowest was -141.00% per year. And the median was -35.70% per year.

Neural Therapeutics  (XCNQ:NURL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Neural Therapeutics EPS (Basic) Related Terms

Neural Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics EPS (Basic) Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
EPS (Basic)
Get a 7-Day Free Trial -0.01 -0.03 -0.02 -0.01 -0.01

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 0.01 0.00 0.00

Neural Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Neural Therapeutics's Basic EPS for the fiscal year that ended in Jul. 2025 is calculated as

Basic EPS (A: Jul. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.026-0)/75.060
=-0.01

Neural Therapeutics's Basic EPS for the quarter that ended in Jan. 2026 is calculated as

Basic EPS (Q: Jan. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-0.391-0)/157.396
=-0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of C$0.00 mean?
Neural Therapeutics (XCNQ:NURL) has a EPS (Basic) of C$0.00 as of Jan. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' EPS (Basic) too high?
Neural Therapeutics' current EPS (Basic) is C$0.00.
How does Neural Therapeutics' EPS (Basic) compare to VRTX and REGN?
Neural Therapeutics' EPS (Basic) of C$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current EPS (Basic) is C$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (XCNQ:NURL) has a current EPS (Basic) of C$0.00. The current EPS (Basic) is C$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Neural Therapeutics (XCNQ:NURL), the current EPS (Basic) is C$0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:Germany
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.